What science
体育外围首页
体育外围首页
Annual Report & Form 20-F
足球外围平台-足球网
One of the Board’s basic responsibilities is to set our strategy and monitor progress towards meeting our objectives, so that we bring our science to patients, create value for society, and reward you, our shareholders.
2017 represented a defining year for AstraZeneca. 2018 will be equally important as we seek to deliver the full potential of our medicines and ensure we deliver our science to patients around the world.
In 2017, our financial performance reflected the launch of several new medicines, the strong performance of our Growth Platforms and the continued impact from patent expiries; most notably for Crestor and Seroquel XR体育外围首页
足球外围平台-足球网
Total Revenue
足球外围平台-足球网
Net cash flow from operating activities
足球外围平台-足球网
Reported operating profit
足球外围平台-足球网
Core operating profit
足球外围平台-足球网
Reported EPS
足球外围平台-足球网
Core EPS
足球外围平台-足球网
足球外围平台-足球网
We are a global biopharmaceutical business delivering medicines to patients through innovative science and excellence in development and commercialisation.
足球外围平台-足球网
足球外围平台-足球网
2016: $21,319m
2015: $23,641m体育外围首页
足球外围平台-足球网
足球外围平台-足球网
体育外围首页
体育外围首页
体育外围首页
体育外围首页
体育外围首页
体育外围首页
足球外围平台-足球网
足球外围平台-足球网
足球外围平台-足球网
足球外围平台-足球网
Pence: 68.9
SEK: 7.40
体育外围首页
足球外围平台-足球网
足球外围平台-足球网
Pence: 133.6
SEK: 14.97
体育外围首页
足球外围平台-足球网
足球外围平台-足球网
Pence: 202.5
SEK: 22.37
体育外围首页
足球外围平台-足球网
We announced our strategy for returning to growth in 2013. We moved on from the first phase in our journey, focused on rebuilding our pipeline, in 2015. The second stage is crucial as we drive our Growth Platforms forward, continue to launch new medicines and make them available to patients. As we look ahead to 2020 and beyond, continued investment in our pipeline will keep us on track to return to sustainable growth in line with our targets.
In 2017, our strategic priorities were focused under the three pillars described below.
-
体育外围首页
We are focusing our science on three therapy areas and accelerating our pipeline. We are also transforming our way of working.
-
体育外围首页
We are focusing on our Growth Platforms and transforming the business through specialty care, devices and biologic medicines. Targeted business development re资讯rces our efforts.
-
体育外围首页
We are evolving our culture and simplifying our business. We want to attract and retain the best talent. We also want to do business sustainably.
足球外围平台-足球网
体育外围首页
体育外围首页
$4,024m
产品介绍 Sales (2016: $3,383m, 2015: $2,825m)
Highlights
- Tagrisso sales up 126% (126% at CER) and approved in more than 60 markets
- Iressa sales of $528 million, up 3% (3% at CER); Lynparza sales of $297 million, up 36% (35% at CER)
- Imfinzi launched in the US in May and sales of $19 million; Calquence launched in the US in October and sales of $3 million
体育外围首页
$7,266m
产品介绍 Sales (2016: $8,116m, 2015: $9,489m)
Highlights
- Brilinta sales of $1,079 million, up 29% (29% at CER) and Forxiga sales of $1,074 million, up 29% (28% at CER)
- Sales of Onglyza were down by 15% (16% at CER) to $611 million
- Legacy sales: Crestor down 30% (30% at CER) to $2,365 million
体育外围首页
$4,706m
产品介绍 Sales (2016: $4,753m, 2015: $4,987m)
Highlights
- Symbicort sales of $2,803 million, down 6% (6% at CER)
- Sales of Pulmicort up 11% (12% at CER) at $1,176 million
- Fasenra approved in the US in November
体育外围首页
$4,156m
产品介绍 Sales (2016: $5,067m, 2015: $6,340m)
Highlights
- Nexium sales down 4% (3% at CER) to $1,952 million
- Sales of Synagis up 1% (1% at CER) to $687 million
- Seroquel XR sales of $332 million, down 55% (55% at CER)
- FluMist/Fluenz sales of $78 million, down 25% (28% at CER)
